MoneyWorks4Me

Alembic Pharmaceuticals informs about press release

27 Jan 2026 Evaluate
Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Final Approval for Difluprednate Ophthalmic Emulsion, 0.05%. Enclosed its press release.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

834.00 11.10 (1.35%)
18-Aug-2026 09:35 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1890.30
Dr. Reddys Labs. 1183.75
Cipla 1432.20
Lupin 2237.00
Zydus Lifesciences 1137.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: